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Abstract
Current knowledge on the pathogenesis of diastolic heart failure predominantly rests on
case-control studies involving symptomatic patients with preserved ejection fraction and
relying on invasive diagnostic procedures including endomyocardial biopsy. Our objective
was to gain insight in serum and urinary biomarkers reflecting collagen turnover and associ-
ated with asymptomatic diastolic LV dysfunction. We randomly recruited 782 Flemish
(51.3% women; 50.5 years). We assessed diastolic LV function from the early and late dia-
stolic peak velocities of the transmitral blood flow and of the mitral annulus. By sequencing
urinary peptides, we identified 70 urinary collagen fragments. In serum, we measured car-
boxyterminal propeptide of procollagen type 1 (PICP) as marker of collagen I synthesis and
tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1), an inhibitor of collagen-degrad-
ing enzymes. In multivariable-adjusted analyses with Bonferroni correction, we expressed
effect sizes per 1-SD in urinary collagen I (uCI) or collagen III (uCIII) fragments. In relation
to uCI fragments, e’ decreased by 0.183 cm/s (95% confidence interval, 0.017 to 0.350;
p = 0.025), whereas E/e’ increased by 0.210 (0.067 to 0.353; p = 0.0012). E/e’ decreased
with uCIII by 0.168 (0.021 to 0.316; p = 0.018). Based on age-specific echocardiographic cri-
teria, 182 participants (23.3%) had subclinical diastolic LV dysfunction. Partial least squares
discriminant analysis contrasting normal vs. diastolic LV dysfunction confirmed the afore-
mentioned associations with the uCI and uCIII fragments. PICP and TIMP-1 increased in
relation to uCI (p<0.0001), whereas these serum markers decreased with uCIII (p0.0006).
Diastolic LV dysfunction was associated with higher levels of TIMP-1 (653 vs. 696 ng/mL;
p = 0.013). In a general population, the non-invasively assessed diastolic LV function
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correlated inversely with uCI and serum markers of collagen I deposition, but positively with
uCIII. These observations generalise previous studies in patients to randomly recruited peo-
ple, in whom diastolic LV function ranged from normal to subclinical impairment, but did not
encompass overt diastolic heart failure.
Introduction
Diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF)
represents half of all heart failure cases. It has a prognosis as dire as heart failure with reduced
ejection fraction with a rate of cardiovascular mortality of over 30% within one year of the first
hospital admission. In patients with diastolic heart failure, the left ventricular (LV) wall under-
goes fibrosis characterised by increased interstitial deposition [1] and cross-linking of collagen
I at the detriment of collagen III [2,3]. Small increases in the collagen I/III ratio augment myo-
cardial stiffness, thereby reducing early diastolic LV filling and increasing LV filling pressure
[4,5]. However, information on the asymptomatic phases of the disease remains scarce. This
knowledge gap is particularly relevant, because the prevalence of asymptomatic diastolic LV
dysfunction in the general population is as high as 25%[6] with a 10% risk of deterioration
over 5 years [7].
Capillary electrophoresis coupled with high-resolution mass spectrometry (CE-MS) enables
detection of over 5000 distinct peptide fragments in urine samples [8]. Our previous studies
revealed a unique urinary proteomic signature, which in case-control studies [9] and in the gen-
eral population [10] was reproducibly associated with subclinical diastolic LV dysfunction and
which predicted the incidence of adverse cardiovascular outcomes over and beyond traditional
cardiovascular risk factors [11]. We hypothesised that jointly linking diastolic LV dysfunction
to urinary and serum markers of collagen turnover might increase our understanding of LV
dysfunction. With the aim to generalise observations in patients with diastolic heart failure [2–
5] to the early still asymptomatic stage of the disease in the population at large, we analysed the
Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO) [10]. First, we
searched for association of diastolic LV function with individual urinary peptides with known
amino-acid sequence, thereby identifying collagen types as the parent proteins. Next, we corre-
lated single urinary peptides significantly associated with diastolic LV function with circulating
markers of cardiac collagen turnover, which in previous studies [5,12] predicted mortality and
cardiovascular events.
Materials and Methods
Study population
FLEMENGHO complies with the Helsinki declaration [13] for research in human subjects. The
Ethics Committee of the University of Leuven approved the study [10]. At each contact, partici-
pants gave informed written consent. Recruitment for FLEMENGHO started in 1985 [10,14–
17]. From August 1985 until November 1990, a random sample of the households living in a
geographically defined area of Northern Belgium was investigated with the goal to recruit an
equal number of participants in each of six subgroups by sex and age (20–39, 40–59, and60
years). All household members with a minimum age of 20 years were invited to take part, pro-
vided that the quota of their sex-age group had not yet been satisfied. From June 1996 until Jan-
uary 2004 recruitment of families continued using the former participants (1985−1990) as
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index persons and also including teenagers. The initial participation rate was 780%. The partic-
ipants were repeatedly followed up at the field centre in the catchment area (North Limburg,
Belgium). From May 2005 until May 2010, an invitation letter was mailed to 1208 former partic-
ipants for a follow-up examination. However, 153 were unavailable, because they had died
(n = 26), had been institutionalised or were too ill (n = 27), or had moved out of the area
(n = 100). Of the remaining 1055 former participants, 828 renewed informed consent [10]. The
participation rate at re-examination was 78.5%. We excluded 46 participants from analysis,
because serum samples were unavailable (n = 22), or because arrhythmia (n = 8), paced heart
rhythm (n = 3) or poor echocardiographic image quality (n = 13) rendered assessment of dia-
stolic LV function difficult. Thus, the number of participants statistically analysed totalled 782.
Echocardiography
The acquisition, offline analysis, staging of diastolic LV function and quality control are exten-
sively described in previous publications [6,7,18] and summarised below.
Data acquisition. One observer (TKu) did the ultrasound examination [6], using a Vivid7
Pro (GE Vingmed, Horten, Norway) device interfaced with a 2.5- to 3.5-MHz phased-array
probe. For off-line analysis, she recorded at least five heart cycles according to the recommen-
dations of the American Society of Echocardiography [19]. M-mode echocardiograms of the
left ventricle (LV) were recorded from the parasternal long-axis under control of the two-
dimensional image. The ultrasound beam was positioned just below the mitral valve at the
level of the posterior tendinous chords. To record the mitral and pulmonary vein (PV) flow
velocities from the apical window, the observer positioned the Doppler sample volume at the
mitral valve tips, in the right superior PV, and between the LV outflow and mitral inflow,
respectively. From the apical window, the observer placed a 5-mm Doppler sample at the sep-
tal, lateral, inferior and posterior sites of the mitral annulus to record low-velocity, high-inten-
sity myocardial signals at a high frame rate (>190 frames per second), while ensuring parallel
alignment of the ultrasound beam with the myocardial segment of interest.
Off-line analysis. One reader (TKu) analysed the digitally stored images, averaging three
heart cycles, using a workstation running EchoPac software, version 4.0.4 (GE Vingmed, Hor-
ten, Norway). LV internal diameter and interventricular septal and posterior wall thickness
were measured at end-diastole from the 2-dimensionally guided M-mode tracing. When opti-
mal orientation of M-mode ultrasound beam could not be obtained, the reader performed lin-
ear measurements on correctly oriented 2-dimensional images. End-diastolic LV dimensions
were used to calculate LV mass [19]. Left atrial (LA) volume was calculated using the prolate-
elipsoid method from the LA dimensions in three orthogonal planes and indexed to body sur-
face area [19]. From the transmitral flow signal, the reader determined peak early diastolic
velocity (E), peak late diastolic velocity (A), the E/A ratio, and the transmitral A flow duration.
From the PV flow signal, she measured the duration of PV reversal flow during atrial systole.
From the tissue Doppler recordings, the observer measured peak early (e’) and peak late (a’)
diastolic mitral annular velocities, and the e’/a’ ratio at the four acquisition sites (septal, lateral,
inferior, and posterior).
Staging of diastolic LV function. S1 Table summarises the physiological interpretation
of the echocardiographic measurements reflecting diastolic LV function. As shown in Fig 1,
guideline-driven echocardiographic criteria to stage patients with advanced diastolic LV
dysfunction [20] leave a large proportion of people unclassified in population studies [6,21].
We therefore developed age-specific criteria in a healthy reference sample drawn from FLE-
MENGHO [6] and replicated these criteria in a European population study [21]. To stage
diastolic LV function in our current study, as previously described [6,21], we combined the
Diastolic LV Function and Collagen Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0167582 December 13, 2016 3 / 17
velocities of the transmitral blood flow and the mitral annular movement. Group 1 included
patients with an abnormally low age-specific transmitral E/A ratio indicative of impaired
relaxation, but without evidence of increased LV filling pressures (E/e’  8.5). Group 2 had
mildly-to-moderately elevated LV filling pressure (E/e’ > 8.5) and an E/A ratio within the
normal age-specific range. Differences in durations between the transmitral A flow (Ad)
and the reverse flow in the pulmonary veins (ARd) during atrial systole (Ad < ARd + 10)
and the left atrial volume index ( 29 mL/m2; the 97.5th percentile of the distribution in a
reference sample of 239 healthy FLEMENGHO participants [6]) were checked to confirm
elevation of LV filling pressure (S1 Table). Group 3 had an elevated E/e’ ratio and an abnor-
mally low age-specific E/A ratio (combined dysfunction). We combined these three groups
for analysis.
Quality control. Intra-observer reproducibility was the 2-SD interval about the mean of
the relative differences across pairwise readings. The intra-observer reproducibility for the tis-
sue Doppler peak velocities across the four sampling sites ranged from 4.5% to 5.3% for e’ and
from 4.0% to 4.5% for a’ [6]. Reproducibility was 2.2% for internal end-diastolic LV diameter,
4.6% for LV wall thickness, and 4.3% for LV mass [18].
Urinary peptides
Participants collected 24-h urine samples within one week of the echocardiographic examina-
tions. Aliquots (0.7 mL) were stored at –80˚C and thawed immediately before analysis. Previ-
ous publications provide a detailed account of the methods applied for preparation of the
urine samples and running the CE-MS analysis [22,23]. For targeted sequencing, urine sam-
ples were analysed on a Dionex Ultimate 3000 RSLS nano flow system (Dionex, Camberly,
UK) or on a Beckman CE, coupled to an Orbitrap Velos MS instrument (Thermo Scientific,
Waltham, Massachusetts, US) [24]. The data files were analysed using Proteome Discoverer
1.2 (precursor mass tolerance, 10 ppm; fragment mass tolerance, 0.05 Da) and were searched
against the UniProt human non-redundant database without enzyme specificity. No fixed
modifications were selected. Oxidation of methionine and proline were considered as variable
modifications. The criteria for accepting sequences were high confidence (Xcorr 1.9) and
absence of unmodified cysteine. A strong correlation between peptide charge at the working
pH of 2 and capillary electrophoresis migration time was used to avoid falsely characterised
peptides [25].
Fig 1. Distributions of: (A) the peak velocity of the mitral annular movement during early diastole (e’); (B) the ratio of the peak velocities
of transmitral blood flow to mitral annular movement in early diastole; and (C) the left atrial volume index (LAVI). In line with the US
guideline (J Am Soc Echocardiogr 2016;29:277–314), e’ was measured at septal wall in panel A, but was the average of the septal and lateral
sample sites in panel B. Arrows indicate the cut-off values for diastolic LV dysfunction recommended for clinical use in patients with advanced
diastolic dysfunction.
doi:10.1371/journal.pone.0167582.g001
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We identified 88 sequenced peptides with mean signal amplitude different from undetect-
able in over 95% of participants. Proteomics and peptidomics data usually display missing val-
ues, which result from either the absence of a particular peptide in certain datasets or from the
fact that this particular peptide may be below of the limit of detection of the technological plat-
form. For the current analysis, the values of peptides undetectable in less than 5% of randomly
varying study participants were set to the minimum of the distribution of each sequenced pep-
tide. This strategy has been validated by other research groups [26,27]. Furthermore, the car-
diac extracellular matrix (ECM) is predominantly composed of fibrillar collagen I (85%) and
III (11%) and small amounts of collagen IV and V co-distributed with collagen I. We therefore
confined our analyses to 70 urinary peptide fragments, which could be traced back to the
aforementioned collagen types (S2 Table).
Circulating biomarkers
On the day of echocardiography, venous blood samples were drawn after at least 8 hours of
fasting. Serum was analysed for carboxyterminal propeptide of procollagen I (PICP), a marker
of collagen I synthesis; carboxyterminal telopeptide of collagen I (CITP) and tissue inhibitor
of the matrix metalloproteinase type 1 (TIMP-1) as markers of degradation of collagen I; and
amino terminal propeptide of procollagen type III (PIIINP), a marker of synthesis and degra-
dation of collagen III (S2 Fig). Serum markers were measured in 740 of 782 participants
(94.6%). As described previously [3], PICP (Quidel Corporation, San Diego, CA), TIMP-1
(GE Healthcare Life Sciences, Buckinghamshire, UK) and PIIINP (MyBioSource, San Diego,
CA) were quantified by sandwich enzyme linked immunosorbent assay and CITP by a quanti-
tative enzyme immunoassay (Orion Diagnostica, Espoo, Finland). The detection limits were
0.2 μg/L for PICP (inter- and intra-assay coefficients of variability, 6.4% and 4.5%), 0.3 μg/L
for CITP (13.1% and 10.0%), 1.25 ng/mL for TIMP-1 (12.8% and 2.6%), and 31.3 pg/mL for
PIIINP (<15.0%) [3].
Other measurements
Blood pressure was the average of five consecutive auscultatory readings obtained according
to European guidelines [28] with a standard mercury sphygmomanometer with the partici-
pant resting in the seated position for at least 10 minutes. Hypertension was a blood pres-
sure of at least 140 mm Hg systolic or 90 mm Hg diastolic or use of antihypertensive drugs.
Body mass index was weight in kilograms divided by height in meters squared. Plasma glu-
cose and serum total and high-density lipoprotein (HDL) cholesterol, creatinine, γ-gluta-
myltransferase (biomarker of alcohol intake) and insulin were measured by automated
methods in a single certified laboratory. Glomerular filtration rate was derived by the
Chronic Kidney Disease Epidemiology Collaboration equation [29]. We graded chronic
kidney disease according to the National Kidney Foundation K/DOQI guideline [30] into
stages 1, 2, 3A, 3B, 4 and 5 based on eGFR values of 90, 60–89, 45–59, 30–44, 15–29 and
<15 mL/min/1.73 m2. Diabetes mellitus was a self-reported diagnosis, a fasting glucose
level of 7 mmol/L or higher, or use of antidiabetic agents [31].
Statistical Analysis
For database management and statistical analysis, we used the SAS system, version 9.4 (SAS
Institute Inc., Cary, NC). Means were compared using the large-sample z-test and proportions
by Fisher’s exact test. We normalised the distributions of γ-glutamyltransferase, insulin and
PIIINP by a logarithmic transformation.
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We identified covariables to be retained in the analyses by a stepwise regression procedure
with p-values for covariables to enter and stay in the models set at 0.15. In continuous analyses,
we standardised diastolic LV function for the average in the whole study population (mean or
ratio) of the covariables identified by stepwise regression. While accounting for covariables, we
regressed the indexes of diastolic LV function on the urinary peptide markers and con-
structed–log10 probability plots. Based on the number of parent collagen proteins (types I, III,
IV and V), we adjusted significance levels by the Bonferroni method. In the next step of our
analyses, we applied partial least squares discriminant analysis (PLS-DA). PLS-DA is a statisti-
cal technique that constructs predictive models for categorical outcomes in relation to corre-
lated high dimensional predictors. PLS-DA allowed us to identify a set of independent latent
factors that were linear combinations of the urinary peptides and that maximised the covari-
ance between the urinary peptides and the variables describing diastolic LV function. We stud-
ied normal vs. diastolic dysfunction in relation to the latent factors. We retained the smallest
number of latent factors for which the predicted residual sums of squares (PRESS, calculated
using leave-one-out cross-validation) did not differ significantly (p>0.10) from the model
with the minimum PRESS value as assessed by the van der Voet T2 statistic. The importance
of each urinary peptide in the construction of the PLS factors and in the association of diastolic
function was assessed from the Variable Importance in Projection (VIP) scores of Wold.
Using principal component analysis, we summarized the urinary peptides with a VIP score
higher than 1.0 and a correlation coefficient of less than –0.04 or higher than 0.04 into a single
factor. Finally, we constructed Receiver Operating Characteristic (ROC) plots and evaluated
the area under the ROC curve (AUC).
Results
Characteristics of participants
Of 782 participants, 401 (51.3%) were women. All were White Europeans. Mean values
(SD) in the 782 participants were 50.5 (15.5) years for age, 26.4 (4.2) kg/m2 for body mass
index, 129.1 (17.5) mm Hg and 79.6 (9.5) mm Hg for systolic and diastolic blood pressure,
and 5.25 (0.97) mmol/L for total cholesterol. Among all participants, 327 (41.8%) had
hypertension, of whom 199 (60.9%) were on antihypertensive drug treatment, and 9 (1.2%)
had diabetes.
The prevalence of diastolic LV dysfunction amounted to 182 (23.3%). Two participants
had tricuspid regurgitation and 10 had an E/e’ ratio exceeding 14. Among participants with
normal or impaired diastolic LV function only two and seven had an ejection fraction of
less than 50%. There was no difference in the ejection fraction between these two groups
(68.2 vs. 69.0%, p = 0.29). Table 1 shows that cardiovascular risk factors were more prevalent
or elevated in participants with diastolic dysfunction compared with those with normal LV
function, with exception of the proportion of women, smokers and patients with diabetes.
Fig 1 shows the distributions of echocardiographic indexes, e’ and E/e’. Diastolic LV dys-
function was characterised by impaired relaxation in 68 patients (37.4%) or an elevated fill-
ing pressure in the presence of a normal (90 [49.5%]) or low (24 [13.2%]) age-specific E/A
ratio [6,21]. The echocardiographic characteristics of participants by these categories of dia-
stolic LV function appear in Table 2. Compared with participants with normal LV function,
patients with diastolic LV dysfunction more frequently (p0.003) used medications: any
diuretic (5.3% vs. 25.3%), loop diuretics (0.2% vs. 2.2%), spironolactone (1.0% vs. 7.7%),
β-blockers (9.0% vs. 36.3%), angiotensin-converting enzyme inhibitors (3.0% vs. 9.3%),
angiotensin I type-1 receptor blockers (2.2% vs. 10.4%) and vasodilators including calcium-
channel blockers and α-blockers (2.8% vs. 11.0%).
Diastolic LV Function and Collagen Biomarkers
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S3 Table lists the covariables considered for entry and retained for multivariable adjustment
of diastolic LV function. Based on the results of the stepwise regression analysis, we standard-
ised all echocardiographic indexes of diastolic function for sex, age, body mass index, mean
arterial pressure, heart rate, serum total cholesterol, γ−glutamyltransferase and creatinine,
plasma glucose, LV mass index and treatment with diuretics, β−blockers and inhibitors of the
renin-angiotensin system.
Urinary biomarkers
In general, urinary peptides derived from collagen I correlated with one another. For instance,
the correlation coefficients relating p70635 to the other collagen I fragments ranged from 0.14
to 0.30 (p<0.0001 for all). The correlation between the two collagen III fragments, p107460
and p112106, was 0.19 (p<0.0001). There was a weak inverse correlation (r = –0.10; p = 0.0054)
between p70635 (collagen I fragment) and p107460 (collagen III fragment).
Among all 782 participants, eGFR averaged 80.7 (16.4) mL/min/1.73 m2. The prevalence
of renal function stages 1, 2, 3A, 3B, 4 and 5 amounted to 175 (22.4%), 552 (70.8%), 49 (6.3%),
Table 1. Characteristics of 782 Participants by Category of the Diastolic LV Function
Characteristic Normal Dysfunction p
Number in category 600 182
Number of subjects (%)
Women 298 (49.7) 103 (56.6) 0.10
Smokers 129 (21.5) 29 (15.9) 0.10
Drinking alcohol 435 (72.5) 107 (58.8) 0.0004
Hypertension 180 (30.0) 147 (80.8) <0.0001
Antihypertensive treatment 97 (53.9) 102 (69.4) <0.0001
Diabetes mellitus 4 (0.7) 5 (2.8) 0.10
Mean (SD) of characteristic
Age (years) 46.4 (13.8) 64.2 (12.7) <0.0001
Body mass index (kg/m2) 25.8 (4.0) 28.6 (4.4) <0.0001
Waist-to-hip ratio 0.86 (0.08) 0.90 (0.08) <0.0001
Office blood pressure (mmHg)
Systolic pressure 125.1 (15.2) 142.2 (18.2) <0.0001
Diastolic pressure 79.0 (9.3) 81.5 (10.1) 0.0021
Mean arterial pressure 94.3 (10.2) 101.7 (10.3) <0.0001
Heart rate (beats per minute) 60.3 (9.2) 62.1 (11.2) 0.053
Biochemical data
Serum creatinine (μmol/L) 82.5 (13.5) 86.9 (20.2) 0.0072
eGFR (mL/min/1.73 m2) 83.2 (16.1) 72.4 (14.6) <0.0001
Total cholesterol (mmol/L) 5.17 (0.96) 5.51 (0.98) <0.0001
HDL cholesterol (mmol/L) 1.44 (0.35) 1.38 (0.35) 0.059
Total-to-HDL cholesterol ratio 3.75 (1.01) 4.17 (1.05) <0.0001
Plasma glucose (mmol/L) 4.84 (0.55) 5.25 (1.25) <0.0001
γ-Glutamyltransferase (units/L) 22 (12–53) 26 (13–51) 0.013
Insulin (pmol/L) 31.0 (13.9–69.5) 40.9 (21.0–89.6) <0.0001
eGFR indicates estimated glomerular filtration rate derived by the Chronic Kidney Disease Epidemiology Collaboration equation formula. Office blood
pressure was the average of five consecutive readings. Hypertension was an office blood pressure of140 mmHg systolic, or90 mm Hg diastolic, or use
of antihypertensive drugs. For γ−glutamyltransferase and insulin reported values are geometric means (interquartile range). Diabetes mellitus was a self-
reported diagnosis, a fasting glucose level of7 mmol/L, or use of antidiabetic agents.
doi:10.1371/journal.pone.0167582.t001
Diastolic LV Function and Collagen Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0167582 December 13, 2016 7 / 17
5 (0.6%), 1 (0.1%) and 0, respectively. With adjustments applied for mean arterial pressure,
waist-to-hip ratio, smoking, γ-glutamyltransferase, the total-to-HDL cholesterol ratio, plasma
glucose, and use of antihypertensive medications by drug class, none of the associations of
eGFR with the urinary collagen fragments reached significance (p0.082).
Continuous analysis
S1 Fig. shows the–log10(p) probability plot of the multivariable-adjusted associations of vari-
ous indexes of diastolic LV function with the urinary peptides. With Bonferroni correction
applied, the urinary peptides that remained significantly associated with the Doppler indexes
of diastolic LV function included six fragments of collagen I (p70635, p72896, p73697, p77018,
p77952 and p115491) and two fragments of collagen III (p107460 and p112106). Focusing on
collagen I (Table 3), e’ peak velocity and the e’/a’ ratio decreased respectively with p70635
(effect size per 1-SD increment, –0.183; p = 0.025) and p77952 (–0.041; p = 0.006), whereas the
E/e’ ratio increased with p72896 (0.164; p = 0.020), p77018 (0.210; p = 0.0012) and p115491
(0.162; p = 0.019). The a’ peak velocity declined with p72896 (–0.192; p = 0.0024) and p73697
(–0.160; p = 0.016). In relation to collagen III fragments, A peak velocity (–1.450; p = 0.0024)
and the E/e’ ratio (–0.168; p = 0.018) declined with p107460 and the A peak also with p112106
(–1.334; p = 0.006). Sensitivity analyses with additional adjustment for HDL cholesterol and
insulin produced confirmatory results (Table 3). None of the indexes of diastolic LV function
was significantly associated with the sequenced collagen IV or V fragments (S2 Table).
Categorical analysis. We dichotomised the study population in 600 participants with nor-
mal LV function and 182 with diastolic LV dysfunction. The PLS-DA procedure yielded two
latent factors accounting for 10.2% and 6.3% of the variance in the urinary peptides and 16.5%
in total.
Using a VIP score of 1.5 and a correlation coefficient of –0.04 as cut-offs, normal diastolic
LV function (Fig 2, left top side of the V-plot) was associated with the collagen I fragments
p35339, p57531, and p91542. Using a VIP score of 1.5 and a correlation coefficient of 0.04 as
cut-offs, diastolic dysfunction (Fig 2, right top side of the V-plot) was associated with collagen
Table 2. Echocardiographic measurements by category of diastolic LV function
Characteristic Normal (n = 600) Dysfunction (n = 182)
Conventional echocardiography
Left atrial volume, mL 40.9 (12.5) 49.3 (15.4)*
Left atrial volume index, mL/m2 21.8 (5.51) 26.7 (7.59)*
Left ventricular mass, g 165.5 (44.7) 194.3 (55.7)*
Left ventricular mass index, g/m2 88.4 (19.0) 104.9 (25.7)*
Doppler data
Deceleration time, ms 159.8 (30.6) 189.2 (45.2)*
Isovolumetric relaxation time, ms 94.7 (14.1) 106.8 (18.0)*
E peak, cm/s 77.7 (14.9) 69.0 (17.3)*
A peak, cm/s 59.1 (13.9) 82.1 (15.8)*
E/A ratio 1.40 (0.46) 0.86 (0.25)*
e’ peak, cm/s 12.6 (3.26) 7.77 (1.89)*
a’ peak, cm/s 9.75 (2.07) 11.1 (1.94)*
e’/a’ ratio 1.42 (0.65) 0.73 (0.26)*
E/e’ ratio 6.38 (1.33) 9.26 (2.78)*
* An asterisk indicates a significant difference with normal.
doi:10.1371/journal.pone.0167582.t002
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I fragment p77763, collagen III fragments p50840 and p105352, and collagen V fragment
p104786. p77763 is a collagen I fragment with an amino-acid sequence very similar to p77018
(one proline residue being replaced by hydroxyproline; S2 Table), which was related to the
indexes of diastolic LV function in the continuous analyses (Table 3 and S1 Fig). In general,
the sequences of collagen I fragments associated with normal diastolic function were shorter
than those associated with dysfunction (S2 Table). The level of the collagen I fragment p77018
was higher in patients with diastolic LV dysfunction than in participants with normal diastolic
function, whereas the opposite was true for the collagen III fragment p107460 (Table 4).
To evaluate diagnostic accuracy, we combined the urinary peptides with a VIP score higher
than 1.5 and a correlation coefficient lower than –0.04 or higher than 0.04 into a single factor
(p35339, p50840, p57531, p77763, p91542, p104786, p105352), using principal component
analysis. The AUC for diagnosing diastolic LV dysfunction was 0.92 (95% CI, 0.89–0.94;
p<0.0001) yielding a sensitivity, specificity and positive and negative predictive values of
67.6%, 93.3%, 75.5% and 90.5%, respectively.
Circulating biomarkers
With adjustments applied for metabolic confounders (body mass index, serum total choles-
terol, γ-glutamyltransferase and creatinine, and plasma glucose) and concurrent treatment by
drug class (Table 4), serum levels of CITP (6.26 vs. 5.34 μg/L), TIMP-1 (696 vs. 653 ng/mL)
and PIIINP (562 vs. 447 pg/mL) were significantly higher (p0.020) in patients with diastolic
LV dysfunction (n = 175) than in people with normal function (n = 565), with no between-
group differences in serum PICP.
Table 5 lists the associations of circulating collagen biomarkers with the urinary collagen I
and III fragments that reached a significance level of 1% or less. With association sizes
Table 3. Multivariable-adjusted associations of tissue Doppler indexes with urinary peptides
Urinary peptides (SD) Collagen Type Model 1 p Model 2 p
Estimate (95% CI) Estimate (95% CI)
A peak
p107460 (863) III –1.450 (–2.502 to –0.398) 0.0024 –1.453 (–2.507 to –0.398) 0.0024
p112106 (3149) III –1.334 (–2.378 to –0.289) 0.006 –1.349 (–2.401 to –0.296) 0.0056
e’ peak
p70635 (728) I –0.183 (–0.350 to –0.017) 0.025 –0.170 (–0.335 to –0.005) 0.041
a’ peak
p72896 (389) I –0.192 (–0.330 to –0.053) 0.0024 –0.193 (–0.332 to –0.055) 0.002
p73697 (521) I –0.160 (–0.298 to –0.022) 0.016 –0.163 (–0.300 to –0.025) 0.013
e’/a’ peak
p77952 (1518) I –0.041 (–0.072 to –0.009) 0.006 –0.038 (–0.070 to –0.006) 0.011
E/e’
p72896 (289) I 0.164 (0.018 to 0.310) 0.020 0.163 (0.017 to 0.309) 0.022
p77018 (1504) I 0.210 (0.067 to 0.353) 0.0012 0.208 (0.065 to 0.351) 0.0012
p107460 (863) III –0.168 (–0.316 to –0.021) 0.018 –0.164 (–0.312 to –0.016) 0.023
p115491 (2362) I 0.162 (0.019 to 0.305) 0.019 0.161 (0.018 to 0.304) 0.020
Abbreviation: CI, confidence interval. All estimates were adjusted for sex, age, body mass index, mean arterial pressure, heart rate, serum total cholesterol,
γ−glutamyltransferase and creatinine, plasma glucose, LVMI and treatment with diuretics, β−blockers and inhibitors of the renin-angiotensin system. Model
2 was additionally adjusted for HDL cholesterol and insulin. Estimates express the change in the dependent variable for 1-SD increase (given between
parentheses) in the urinary peptide. P-values are Bonferroni adjusted.
doi:10.1371/journal.pone.0167582.t003
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expressed per 1-SD increment in collagen I fragments, PICP, CITP and PIIINP increased
(p0.0016) by 14.9 μg/L, 0.31 μg/L and 4.63% in relation to p73697. TIMP-1 increased by
21.4 ng/mL (p = 0.0013) and by 39.4 ng/mL (p<0.0001) in relation to p77018 and p77763,
respectively. The association sizes of PICP, CITP and TIMP-1 with collagen III fragments
amounted to –5.39 μg/L, –0.62 μg/L and –30.9 ng/mL for p107460 (p0.0006) and to –
0.44 μg/L for CITP.
Discussion
The novel findings in our article, all obtained in a general population, can be summarised as
follows: (i) the correlations between urinary collagen I and III fragments were inverse; (ii) in
continuous analyses, e’ peak and e’/a’ decreased and E/e’ increased with urinary collagen I
fragments, whereas the A peak and E/e’ decreased with urinary collagen III fragments (S1 Fig
and Table 3); (iii) the PLS-DA analysis contrasting normal vs. diastolic LV dysfunction
Fig 2. V-plots generated for the PLS DA derived VIP scores versus the centred and rescaled correlation coefficients. We dichotomised the study
population in 600 participants with normal LV function and 182 with subclinical diastolic LV dysfunction. VIP is the importance of each urinary fragments in the
construction of the PLS factors. The correlation coefficients reflect the association of diastolic LV dysfunction with the urinary collagen fragments. Fragments
associated with normal and diastolic LV dysfunction were sitting on the left and right arms, respectively (see Table 3). Fragments derived from collagen I, III,
IV and V are labelled blue, red, yellow and green, respectively.
doi:10.1371/journal.pone.0167582.g002
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confirmed the associations with urinary collagen I and III fragments (Fig 2); (iv) PICP, CITP
and TIMP-1 increased in relation to urinary collagen I fragments, whereas these serum mark-
ers decreased in relation to urinary collagen III (Table 5); and (v) in categorical analyses, dia-
stolic LV dysfunction was associated with higher levels of urinary collagen I fragments, lower
levels of urinary collagen III degradation products, and higher levels of CITP and TIMP-1, but
not PICP (Table 4).
Collagen I is a stiff fibrillar protein providing tensile strength, whereas collagen III forms an
elastic network storing kinetic energy that is released during elastic recoil [32]. Histopatholog-
ical [33–35] and expression [34] studies of endomyocardial biopsies suggested that in humans
chronic heart failure with preserved ejection fraction is characterised by myocardial fibrosis
with a predominant increase in collagen I. Zile and colleagues measured myocardial stiffness
directly in myocardial biopsies of 70 patients undergoing coronary artery bypass grafting [36].
In comparison with controls without comorbidity and controls with hypertension, patients
with hypertension and diastolic heart failure had an increased end-diastolic LV pressure, left
atrial volume, and collagen-dependent passive stiffness [36]. In keeping with experimental
studies in rats [37], among patients with dilated cardiomyopathy [32], tissue samples of
patients with heart failure compared with those from controls with mild global LV dysfunction
had a 2- to 6-fold increase in collagen I mRNA, a 2-fold increase in collagen III mRNA, result-
ing in a higher collagen I/III expression ratio (8.6 vs. 6.4). Our current findings are novel,
because they show in a general population that echocardiographic indexes of diastolic LV
function are associated with sequenced urinary collagen I and III fragments (S1 Fig and
Table 3). In addition, the I/III ratio of urinary collagen fragments was higher in patients with
diastolic LV dysfunction compared to participants with normal LV function (Table 4). Thus,
sequencing of the urinary peptide fragments allowed us to translate previous observations in
endomyocardial biopsies [32–35] to people randomly recruited from the general population,
in whom diastolic LV function ranged from normal to subclinical dysfunction, but did not
encompass overt diastolic heart failure.
During the cardiac cycle, the left atrium acts as a reservoir, receiving pulmonary venous
return during LV systole; as a conduit, passively transferring blood to the LV during early dias-
tole; and as a pump, actively priming the LV in late diastole [38]. Stiffening of the LV requires
Table 4. Serum and urinary biomarkers by category of diastolic LV function
Biomarkers Unadjusted Adjusted
Normal Dysfunction p Normal Dysfunction p
Urine n = 600 n = 182 n = 600 n = 182
p77018 (I) 2751 (56) 3162 (136) 0.0056 2770 (63) 3099 (121) 0.020
p107460 (III) 1788 (35) 1515 (63) 0.0002 1767 (35) 1585 (68) 0.022
p77018/p107460 (I/III) 2.40 (0.19) 4.15 (0.68) 0.015 2.49 (0.25) 3.87 (0.47) 0.0013
Serum n = 565 n = 175 n = 565 n = 175
PICP, μg/L 103.7 (1.9) 90.8 (2.8) 0.0002 100.1 (1.8) 102.7 (3.6) 0.54
CITP, μg/L 5.41 (0.08) 6.05 (0.19) 0.003 5.34 (0.09) 6.26 (0.19) <0.0001
TIMP1, ng/mL 634 (7) 755 (16) <0.0001 653 (7) 696 (15) 0.013
PIIINP, pg/mL 457 (175–1160) 513 (180–1355) 0.15 447 (175–1160) 562 (180–1355) 0.020
Abbreviations: PICP, carboxyterminal propeptide of procollagen I; CITP, carboxyterminal telopeptide of collagen I; TIMP-1, tissue inhibitor of the matrix
metalloproteinase type 1; PIIINP, aminoterminal propeptide of procollagen III. Values are arithmetic mean (SE) or geometric mean (interquartile range).
Adjustments included body mass index, serum total cholesterol, γ−glutamyltransferase and creatinine, plasma glucose, and treatment with diuretics, β
−blockers and inhibitors of the renin-angiotensin system.
doi:10.1371/journal.pone.0167582.t004
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a greater contribution of the atrial contraction to late diastolic LV filling and is associated
with a higher a’ peak velocity. Next, as diastolic LV function deteriorates, the a’ peak velocity
decreases [39]. This so-called pseudo-normalisation (moderate diastolic LV dysfunction in
S1 Table) might therefore underlie the inverse association between a’ peak velocity and urinary
collagen I fragments, as observed in our current study (Table 3). However, excluding 13
patients with an e’/a’ ratio higher than unity or all patients with an E/e’ ratio exceeding 8.5 [6]
did not confirm this interpretation. An alternative explanation is that worsening of diastolic
LV function leads to collagen deposition in the atria [40] with higher collagen I/III ratio [40],
impairment of the atrial reservoir function [41], increase in the left atrial volume [36], deterio-
ration of electromechanical coupling [40], and therefore to lower a’ peak velocity.
PICP is released in a 1:1 stoichiometric ratio during conversion of procollagen I to collagen
I (S2 Fig) and therefore its serum concentration is a direct indicator of concurrent collagen I
synthesis [42]. In patients with hypertensive heart disease [43], circulating PICP, at least in
part, originates from the heart, because there is a positive concentration gradient from the cor-
onary sinus towards the antecubital vein with a high correlation between coronary and periph-
eral levels. This association was not present in normotensive controls [42]. Moreover, serum
PICP concentration correlates well with histologically proven myocardial collagen type I depo-
sition [44] and in response to pharmacological intervention changes in serum PICP associate
with changes in myocardial collagen type I deposition [45]. Our current study moves the field
forward by showing that in the general population PICP increased in relation to p73697, a uri-
nary collagen I fragment, but decreased in relation to p107460, a marker of the more elastic
[32] collagen III (Table 5).
Metalloproteinases catalyse the degradation of collagen I resulting in the release of CITP
in a 1:1 stoichiometric ratio (S2 Fig). The role of CITP as a reliable biomarker of collagen
breakdown is not firmly established, because its association with myocardial fibrosis was
inconsistently reported as negative [46] or positive [47]. Notwithstanding the uncertainty in
the clinical interpretation of circulating CITP levels, our study (Table 5) revealed that serum
CITP correlated positively with p73697, a urinary collagen I fragment associated with worse
diastolic LV function, and inversely with p107460, a urinary marker of collagen III breakdown
associated with more performant diastolic LV function.
Table 5. Association of urinary collagen fragments with serum biomarkers of collagen turnover
Urinary marker (SD) Collagen I Urinary marker (SD) Collagen III
Serum markers Estimate (95% CI) p Serum markers Estimate (95% CI) p
p73697 (521) p107460 (863)
PICP, μg/L 14.9 (12.0 to 17.8) <0.0001 PICP, μg/L –5.39 (–8.47 to –2.31) 0.0006
CITP, μg/L 0.31 (0.16 to 0.47) <0.0001 CITP, μg/L –0.62 (–0.76 to –0.47) <0.0001
PIIINP, % 4.63 (1.77 to 7.50) 0.0016 TIMP-1, ng/mL –30.9 (–43.9 to –18.0) <0.0001
p77018 (1504) p112106 (3149)
TIMP-1, ng/mL 21.4 (8.36 to 34.5) 0.0013 CITP, μg/L –0.44 (–0.59 to –0.29) <0.0001
p77763 (991)
TIMP-1, ng/mL 39.4 (26.5 to 52.2) <0.0001
Abbreviations: CI, confidence interval; PICP, carboxyterminal propeptide of procollagen I; CITP, carboxyterminal telopeptide of collagen I; TIMP-1, tissue
inhibitor of the matrix metalloproteinase type 1; PIIINP, aminoterminal propeptide of procollagen type III. Estimates express the change in the serum
biomarkers per 1-SD increase in urinary collagen fragments. The urinary peptides were identified in the continuous analyses (S1 Fig and Table 3) with the
exception of p77763, which was a marker of diastolic LV dysfunction in the PLS-DA analysis (Fig 2) and had an amino-acid sequence very similar to that of
p77018 (one proline residue being replaced by hydroxyproline; S2 Table).
doi:10.1371/journal.pone.0167582.t005
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Circulating TIMP-1 inhibits the metalloproteinases and is a pro-fibrotic stimulus. Similar
to PICP [43], a positive gradient and a direct correlation exist between the TIMP-1 concentra-
tions in coronary sinus and antecubital vein blood in patients with hypertensive heart disease,
but not in normotensive controls [33]. In hypertensive patients with heart failure but normal
ejection fraction, elevated estimated capillary wedge pressure compared with normal LV filling
pressure was associated with higher TIMP-1 levels and a lower metalloproteinase-1 to TIMP-1
ratio, indicative of lower breakdown of collagen [48]. Zile and coworkers confirmed that in
patients with hypertension with or without diastolic heart failure, circulating TIMP-1 levels,
but not metalloproteinases, were elevated compared to normotensive controls [36]. Our study
moves current knowledge forward by demonstrating that in a general population diastolic LV
dysfunction was associated with higher levels of TIMP-1 (Table 4) and that TIMP-1 increased
in relation to urinary collagen I fragments (Table 5). By linking circulating TIMP-1 to urinary
collagen I fragments, our observation support the hypothesis that an excess of TIMP-1 inhibits
collagen degradation, thereby promoting collagen deposition in the myocardium and diastolic
LV dysfunction characterised by higher LV filling pressure [42]. On the other hand, the uri-
nary collagen III fragment p107460 was associated with better diastolic LV function and lower
LV filling pressure (Table 3 and Fig 2) and lower levels of TIMP-1 (Table 5). In patients with
heart failure due to ischaemic heart disease or dilated cardiomyopathy [37], serum PIIINP lev-
els are highly correlated with the myocardial collagen III volume fraction. The positive associa-
tion between the urinary collagen I fragment p73697 and circulating PIIINP (Table 5), formed
in a 1:2 stoichiometric ratio during the conversion of procollagen III to mature collagen III (S2
Fig), probably reflects the joint increase in both collagen subtypes [49] during myocardial
fibrosis.
Strong points of our study are the availability of Doppler indexes of early subclinical dia-
stolic LV dysfunction measured on a continuous scale, the application of two approaches in
the statistical analysis, and the demonstration of a pathophysiologically plausible correlation
between sequenced urinary collagen fragments and the serum biomarkers of collagen turn-
over. The epidemiological angle enhances the relevance of our findings over and beyond that
of case-control studies involving selected heart failure patients, who represent the end stage
of a long pathogenetic process confounded by multiple comorbidities and poly-medication.
However, our present study must also be interpreted within the context of its limitations. First,
our findings originate from a cross-sectional analysis and therefore reflect a snapshot in each
individual participant. From this point of view our results should be considered as hypothesis
generating. Whether or not, the urinary proteomic and serum biomarkers can predict the
course over time of diastolic LV dysfunction remains to be confirmed in longitudinal studies.
Second, the pathogenetic drivers leading to diastolic LV dysfunction are multifaceted each
with different contributions among people at risk. Whether or not, the urinary collagen mark-
ers can predict the course over time of diastolic LV dysfunction remains to be proven in longi-
tudinal studies. Third, we could not apply the simplified US criteria for the diagnosis of
diastolic LV dysfunction in clinical practice (Fig 1) for the simple reason that they do not align
with the gradation from normal to impaired diastolic function in the general population. How-
ever, our classification system passed expert peer review [7,9–11,18,21]. Finally, epidemiologi-
cal studies demonstrate association and the causal interpretation of associations between traits
of interest and biomarkers rests on a careful interpretation of the literature.
In conclusion, by sequencing urinary collagen I and III fragments and by linking diastolic
LV function with urinary and serum collagen biomarkers, our current findings generalize pre-
vious observations in patients to the population at large. Our current observations support the
concept of porting the use of multidimensional biomarkers measured on diverse platforms or
in different media, e.g. urine and serum, to clinical practice to enable a personalised approach
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to the diagnosis, prevention and treatment of diastolic LV dysfunction, a high-risk condition
[7] that affects 25% of the general population [6]. Furthermore, our current study highlights
research tracks to be pursued in the future, such as showing parallelism between concomitant
changes in diastolic LV function and biomarkers in longitudinal studies and proving concor-
dance in the proteomic profiles of urine, serum or plasma and the myocardium.
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